Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib

Table 2 Overall survival of each cohort by single-nucleotide polymorphisms

		SNP alleles (A/G)	Patients at risk	Events	Median OS (95%CI), months	P value (log-rank)
BCLC1cohort			82	75	18.81 (14.76-23.58)
BCLC2 cohort			79	47	18.32 (13.05-26.44)
Northern Italy cohort			221	180	14.3 (11.84-17.99)
Naples cohort			69	57	9.9 (7.69-12.82)
BCLC1 cohort	AGT1 (rs699)		82	75		0.16
		AA	26	23	18.73 (11.84-41.4)
		AG	34	33	18.43 (10.75-22.76)
		GG	22	19	18.81 (9.67-30.42)
	AGT2 (rs4762)		82	75		0.4
		AA	5	5	41.34 (0.39-74.12)
		AG	16	15	13.95 (7.3-23.87)
		GG	61	55	19.11 (14.86-24.47)
BCLC2 cohort	AGT1 (rs699)		79	47		0.15
		AA	25	15	23.74 (7.46-26.5)
		AG	35	19	21.74 (11.15-33.77)
		GG	19	13	6.64 (3.42-30.29)
	AGT2 (rs4762)		79	47		0.3
		AA	3	1	NE (13.61-NE)
		AG	10	5	30.29 (3.88-32.69)
		GG	66	41	16.41 (8.78-23.74)
Northern Italy cohort	AGT1 (rs699)		220	179		0.5
		AA	72	58	13.58 (10.92-19.2)
		AG	101	83	17.59 (10.85-20.68)
		GG	47	38	12.43 (8.81-20.68)
	AGT2 (rs4762)		221	180		0.7
		AA	5	2	NE (1.94-NE)
		AG	44	36	14.3 (7.46-20.68)
		GG	172	142	14.9 (11.25-18.09)
Naples cohort	AGT1 (rs699)		69	57		0.7
		AA	22	19	12.66 (6.15-18.25)
		AG	38	31	8.32 (4.9-11.71)
		GG	9	7	10.95 (2.6-21.83)
	AGT2 (rs4762)		69	57		0.6
		AG	15	11	9.8 (2.89-24.93)
		GG	54	46	10.1 (7.14-12.82)

NE: Not estimable; OS: Overall survival; 95%CI: 95% confidence interval; SNP: Single-nucleotide polymorphisms; BCLC: Barcelona clinic liver cancer.